# A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity

> **NCT04940078** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 40 (actual)

## Conditions studied

- Obesity & Overweight

## Interventions

- **DRUG:** Cagrilintide
- **DRUG:** semaglutide
- **DRUG:** Cagrilintide and semaglutide

## Key facts

- **NCT ID:** NCT04940078
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-07
- **Primary completion:** 2022-01-19
- **Final completion:** 2022-02-16
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04940078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04940078, "A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04940078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*